Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-2592
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials ; volume:38 ; number:4 ; day:27 ; month:4 ; year:2018 ; pages:539 ; date:5.2018
Journal of clinical immunology ; 38, Heft 4 (27.4.2018), 539, 5.2018
- Urheber
-
Ballow, Mark
- Beteiligte Personen und Organisationen
-
Wasserman, Richard L.
Jolles, Stephen
Chapel, Helen
Berger, Mel
Misbah, Siraj A.
SpringerLink (Online service)
- DOI
-
10.1007/s10875-018-0504-0
- URN
-
urn:nbn:de:101:1-2018091220470433265888
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ballow, Mark
- Wasserman, Richard L.
- Jolles, Stephen
- Chapel, Helen
- Berger, Mel
- Misbah, Siraj A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
Adverse reactions to biologics
New Frontiers in Subcutaneous Immunoglobulin Treatment
Neurological adverse reactions to anticancer drugs
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Impact of COVID-19 on adverse reactions to subcutaneous specific immunotherapy in children:a retrospective cohort study
A single centre retrospective study of systemic reactions to subcutaneous immunotherapy
Adverse drug reactions
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
Overbaked: assessing and predicting acute adverse reactions to Cannabis
Systemic reactions to subcutaneous allergen immunotherapy: real-world cause and effect modelling
Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
Adverse reactions to biologics
New Frontiers in Subcutaneous Immunoglobulin Treatment
Neurological adverse reactions to anticancer drugs
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Impact of COVID-19 on adverse reactions to subcutaneous specific immunotherapy in children:a retrospective cohort study
A single centre retrospective study of systemic reactions to subcutaneous immunotherapy
Adverse drug reactions
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
Overbaked: assessing and predicting acute adverse reactions to Cannabis
Systemic reactions to subcutaneous allergen immunotherapy: real-world cause and effect modelling
Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
Adverse reactions to biologics
New Frontiers in Subcutaneous Immunoglobulin Treatment
Neurological adverse reactions to anticancer drugs
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Impact of COVID-19 on adverse reactions to subcutaneous specific immunotherapy in children:a retrospective cohort study
A single centre retrospective study of systemic reactions to subcutaneous immunotherapy
Adverse drug reactions
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
Overbaked: assessing and predicting acute adverse reactions to Cannabis
Systemic reactions to subcutaneous allergen immunotherapy: real-world cause and effect modelling